Global ETD Search

Pharmakogenetik des Zytostatikums Melphalan: Charakterisierung des Membrantransportes

Kühne, Annett2012

… aufgrund erblich bedingter Faktoren. Melphalan (Alkeran®, L-PAM, L-Phenylalanin-mustard) wird als alkylierendes Zytostatikum erfolgreich in der Therapie des Multiplen Myeloms eingesetzt. Dabei wird eine erhebliche interindividuelle Variabilität in der Pharmakokinetik von Melphalan nach …

goettingen Repository record for Pharmakogenetik des Zytostatikums Melphalan: Charakterisierung des Membrantransportes (opens in a new tab)

The Role of Small Peptides in Cancer Physiology and Chemotherapy

Tsay, Bao-Ling2019

… to permeant metabolites, in targeting the drug melphalan to mouse Ehrlich ascites tumor cells. The dipeptide beta-alanyl-melphalan was synthesized and tested in vitro for toxicity towards mouse Ehrlich ascites tumor cells, mouse liver cells, and mouse 3T3 embryonic cells. The parent compound, …

odu Repository record for The Role of Small Peptides in Cancer Physiology and Chemotherapy (opens in a new tab)

Η ΕΠΙΔΡΑΣΗ ΤΗΣ ΒΙΤΑΜΙΝΗΣ Α ΚΑΙ ΤΟΥ ΣΥΝΔΥΑΣΜΟΥ ΤΗΣ ΜΕ MELPHALAN ΚΑΙ ΚΑΦΕΙΝΗ ΣΤΑ ΑΝΘΡΩΠΙΝΑ ΛΕΜΦΟΚΥΤΤΑΡΑ. (ΚΥΤΤΑΡΟΓΕΝΕΤΙΚΗ ΜΕΛΕΤΗ)

Μυρτσιώτης, ΑντώνιοςAristotle University Of Thessaloniki (AUTH)1985

greece Repository record for Η ΕΠΙΔΡΑΣΗ ΤΗΣ ΒΙΤΑΜΙΝΗΣ Α ΚΑΙ ΤΟΥ ΣΥΝΔΥΑΣΜΟΥ ΤΗΣ ΜΕ MELPHALAN ΚΑΙ ΚΑΦΕΙΝΗ ΣΤΑ ΑΝΘΡΩΠΙΝΑ ΛΕΜΦΟΚΥΤΤΑΡΑ. (ΚΥΤΤΑΡΟΓΕΝΕΤΙΚΗ ΜΕΛΕΤΗ) (opens in a new tab)

Clinical resistance to platinum chemotherapy in ovarian cancer

Newton, C.UCL (University College London)2009

… patient tumours incubated ex vivo with {50\mu}M melphalan, the percent decrease in tail moment at the peak of crosslinking was 41.4 {\pm11.2}, and 44.6 {\pm7.6}, respectively. 24 hours later the percentage repair was 3.1 {\pm25.6} for untreated and 2.8 {\pm26.3} for treated tumours. In …

ucl Repository record for Clinical resistance to platinum chemotherapy in ovarian cancer (opens in a new tab)

Purging e alte dosi di chemioterapia con reinfusione di cellule staminali autologhe in linfomi non Hodgkin follicolari resistenti/refrattari

Bassi, Simona <1973>Alma Mater Studiorum - Università di Bologna2008

… regimen was based on Mitoxantrone 60mg/mq + Melphalan 180 mg/mq, followed by SC re-infusion 24-hours later and G-CSF starting 24 hours after re-infusion. In 19 pts the SC underwent purging: in 10 harvests the CD34+ were selected by immunomagnetic beads, while in the other 9 pts, only …

bologna Repository record for Purging e alte dosi di chemioterapia con reinfusione di cellule staminali autologhe in linfomi non Hodgkin follicolari resistenti/refrattari (opens in a new tab)

Characterisation and Screening of secondary metabolites from Commiphora viminea (Burtt Davy, Burseraceae) Engl. for antifungal properties against Candida auris

Rasalanavho, Rivhashandu Confidence2026

… surpassing the activity of the standard drug melphalan at certain concentrations. This selective toxicity suggests the presence of potent antiproliferative compounds, possibly lignans, terpenoids, or flavonoid derivatives, which inhibit cancer cell growth while sparing normal cells. The …

venda Repository record for Characterisation and Screening of secondary metabolites from Commiphora viminea (Burtt Davy, Burseraceae) Engl. for antifungal properties against Candida auris (opens in a new tab)